Caribou Biosciences

CRBU

Market cap $142M

1.52 USD

-0.07

4.4%

At close Updated Feb 12, 4:00 PM EST

Pre-market

After hours

1.52

0.00

1 day

-4.4%

5 days

1 month

-3.8%

3 months

-32.74%

6 months

-15.08%

Year to date

-4.4%

1 year

17.83%

5 years

-90.69%

10 years

-90.69%

About: Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

Employees: 147

Healthcare Biotechnology